San Francisco, 04 April, Spinal Muscular Atrophy (SMA) Treatment Market
Size, Share & Trends Analysis Report By Route of Administration (Oral,
Intrathecal), By Treatment (Gene Therapy, Drug), By Disease Type, And Segment
Forecasts, 2018 – 2025.
The global spinal muscular atrophy (SMA) treatment market size is expected to reach USD 3.9
billion by 2025, according to a new report by Grand View Research, Inc. It is
estimated to register a CAGR of 12.9% during the forecast period. Due to the
rare nature and complexity of these diseases, scientific knowledge pertaining
to them is scarce. However, there are various initiatives undertaken to
increase awareness regarding rare diseases and to support SMA communities. This
is anticipated to boost the market development over the coming years.
Various
SMA communities and companies have collaborated for developing disease
treatment therapy. For example, RG7916, which is an investigational therapy
being developed by Roche in collaboration with SMA Foundation and PTC
Therapeutics. Thus, heavy investments in R&D by major companies are also
projected to contribute toward the growth of this market. CureSMA, SMA
Foundation, and SMA Europe are some of the organizations actively supporting
R&D pertaining to SMA.
CureSMA
provided funding to a research project to Biogen and Ionis Pharmaceuticals,
Inc. for developing Spinraza, which received U.S. FDA approval in 2016. This
organization has invested nearly USD 70 million in the research pertaining to
SMA, which also included a planned investment of USD 5 million in the coming
years.
Access Full
Research Report On Spinal Muscular Atrophy (SMA) Treatment Market Analysis:
Further key findings from the study suggest:
·
The global spinal muscular
atrophy treatment market is projected to expand at a CAGR of 12.9% over the
forecast period
·
Based on disease type, type 1
accounted for the largest revenue share owing to rising incidence of type 1 SMA
·
By treatment, the drug segment
accounted for the largest revenue share in 2017
·
North America will retain its
lead as the largest regional market; however Asia Pacific is anticipated to
register the fastest CAGR over the forecast period
·
Themarket is presently led by
Biogen Inc. Biogen’s Spinraza is the only approved commercialized treatment for
SMA, owing to which market is not competitive. However, this trend is expected
to change after the commercialization of other treatment therapies post 2020
Browse More Reports Of This
Category By Grand View Research At: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global spinal muscular atrophy treatment market on the basis of
disease type, treatment, route of administration, and region:
SMA
Treatment Disease Type Outlook (Revenue, USD Million, 2015 - 2025)
·
Type 1
·
Type 2
·
Type 3
·
Type 4
SMA
Treatment Outlook (Revenue, USD Million, 2015 - 2025)
·
Gene Therapy
·
Drug
o
Spinraza
o
RG6083 (Olesoxime)
o
RG7916
SMA
Treatment Route of Administration Outlook (Revenue, USD Million, 2015 - 2025)
·
Oral
·
Intrathecal
SMA
Treatment Regional Outlook (Revenue, USD Million, 2015 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Mexico
o
Brazil
·
Middle East & Africa
o
South Africa
Access Full
Press Release of this Report: https://www.grandviewresearch.com/press-release/global-spinal-muscular-atrophy-sma-treatment-market
About Grand
View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
For more
information: www.grandviewresearch.com/
No comments:
Post a Comment